Received: 8 April 2021
Accepted: 19 April 2022
First Online: 10 May 2022
: The study was declared to the National Commission for Information Technology and Civil Liberties (CNIL) the number R04-051. All clinical work was conducted in compliance with current Good Clinical Practices as referenced in the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guidelines, local regulatory requirements and the principles of the Declaration of Helsinki. All patients enrolled in the study provided information before their participation. All clinical sites were required to sign a study-specific site blinding plan. This study is registered on ClinicalTrials. gov (NCT03687112).
: Not applicable.
: The authors declare that they have no competing interests.